Get the Stockscreener App
1.29
0.00%
0.00
After Hours:
1.29
Pliant Therapeutics Inc stock is traded at $1.29, with a volume of 211.63K.
It is up +0.00% in the last 24 hours and up +18.35% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.29
Open:
$1.29
24h Volume:
211.63K
Relative Volume:
0.18
Market Cap:
$79.27M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.4175
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
+0.00%
1M Performance:
+18.35%
6M Performance:
-30.65%
1Y Performance:
-15.13%
1-Day Range:
$1.27
$1.30
1-Week Range:
$1.23
$1.325
52-Week Range:
$1.09
$1.95
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.29 | 79.27M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
Pliant Therapeutics Extends Stockholder Rights Agreement Expiration - TipRanks
PLRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pliant Therapeutics (PLRX) extends stockholder rights plan expiration to 2027 - Stock Titan
Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference - Yahoo Finance
PLRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Pliant Therapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Momentum Shift: Is M I Homes Inc currently under institutional pressure2025 Technical Overview & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PLRX: Lead oncology program shows strong early efficacy and safety, with phase Ib starting in Q2 - TradingView
PLRX Technical Analysis | PLIANT THERAPEUTICS INC (NASDAQ:PLRX) - ChartMill
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration - Seeking Alpha
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference - The Manila Times
Pliant Therapeutics (PLRX) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Investment Recap: What is the Moat Score of Pliant Therapeutics IncJuly 2025 Patterns & AI Optimized Trade Strategies - baoquankhu1.vn
PLRX Should I Buy - Intellectia AI
Should I hold or sell Pliant Therapeutics Inc. stock in 20252025 Winners & Losers & Short-Term Swing Trade Alerts - mfd.ru
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus
Woodline Partners (PLRX) discloses 3.3% beneficial stake in Pliant - Stock Titan
PLRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Chart Watch: What is Pliant Therapeutics Inc.’s book value per shareEarnings Growth Report & Weekly High Potential Stock Alerts - mfd.ru
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Short Interest Up 21.0% in January - MarketBeat
Idiopathic Pulmonary Fibrosis Market: Expanding Revenue - openPR.com
Aug Analyst Calls: Is GENC on track to beat earningsQuarterly Risk Review & High Conviction Buy Zone Alerts - baoquankhu1.vn
Portfolio Shifts: Is Pliant Therapeutics Inc. a potential multi baggerJuly 2025 Levels & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Weekly Earnings: How cyclical is Pliant Therapeutics Incs revenue streamExit Point & Scalable Portfolio Growth Methods - baoquankhu1.vn
Breakout Zone: Why is Pliant Therapeutics Inc stock going upJuly 2025 Macro Moves & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of “Reduce” from Analysts - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of "Reduce" from Analysts - MarketBeat
Citadel Advisors LLC Acquires Additional Shares in Pliant Therapeutics Inc - GuruFocus
Quarterly Earnings: Is Pliant Therapeutics Inc a stock for growth or value investorsJuly 2025 Levels & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
What’s the beta of Pliant Therapeutics Inc. stockQuarterly Trade Report & Entry Point Confirmation Signals - mfd.ru
Pliant Therapeutics COO Kuo Minnie Sells $8853 in Shares By Investing.com - Investing.com UK
Pliant Therapeutics CHRO Cheung sells $9.6k in stock By Investing.com - Investing.com Nigeria
Bernard Coulie Sells 89,375 Shares of Pliant Therapeutics (NASDAQ:PLRX) Stock - MarketBeat
Pliant Therapeutics CHRO Cheung sells $9.6k in stock - Investing.com
Pliant therapeutics CFO Cummings sells $30,722 in stock By Investing.com - Investing.com Canada
Pliant therapeutics CEO Coulie sells $114k in shares By Investing.com - Investing.com Canada
Pliant therapeutics CEO Coulie sells $114k in shares - Investing.com
Pliant Therapeutics COO Kuo Minnie Sells $8853 in Shares - Investing.com
Aug Analyst Calls: Does Costamare Bulkers Holdings Limited stock reflect fundamentalsJobs Report & Verified Momentum Stock Alerts - baoquankhu1.vn
Analysis Recap: Is Pliant Therapeutics Inc benefiting from interest rate changesJuly 2025 WrapUp & Weekly High Momentum Picks - baoquankhu1.vn
Pliant Therapeutics Reports Improved Q3 2025 Results - MSN
Breakout Move: Whats the beta of Pliant Therapeutics Inc stock2025 Technical Patterns & AI Powered Market Entry Strategies - baoquankhu1.vn
Risk Check: What sentiment indicators say about Pliant Therapeutics Inc stockEarnings Risk Summary & Reliable Volume Spike Alerts - Bộ Nội Vụ
Pliant Therapeutics CFO sells $225,679 in stock - MSN
Is Pliant Therapeutics Inc. (9PT) stock prepared for digital transitionJuly 2025 Big Picture & Short-Term High Return Strategies - ulpravda.ru
Retail Trends: Is Pliant Therapeutics Inc. (9PT) stock worth holding before Fed meetingBreakout Watch & Safe Entry Zone Tips - Улправда
Can Pliant Therapeutics Inc. stock double in next 5 yearsStability vs Neutral Overview & HOKA model picks for your routine - Улправда
Will Pliant Therapeutics Inc. (9PT) stock beat revenue estimates2025 Biggest Moves & Daily Growth Stock Investment Tips - Улправда
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):